Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss ...

As the new year sparks a wave of weight loss resolutions and millions turn to weight loss medications, rising costs and the growing popularity of compounded alternatives have raised critical questions ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

In the pursuit of optimal health and wellness, hydration often takes center stage. Many individuals, particularly seniors, ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to ...

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...